Childhood cancers: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 97
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• ABL1 2
• NF1 12
• HER2 25
• PI3K 5
• PD-L1 13
• AKT 1
• CDK4/6 7
• NTRK 10
• B7-H3 15
• mTOR 2
• NMDA 0
• RB1 1
• PSMA 20
• KMT2A 12
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• CD38 5
• EZH2 0
• RAS 1
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 941 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

  NCT02992964· The Hospital for Sick Children· Updated 5 Nov 2026

  “Withdrawal of drug supply/funding”Registry text, quoted unchanged. Source

• Withdrawn

  xPedite: A Study to Expedite DIPG and DMG Research

  NCT06140719· xCures· Updated 2 Nov 2026

  “Protocol termination”Registry text, quoted unchanged. Source

• Suspended

  PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

  NCT06639607· Washington University School of Medicine· Updated 30 Oct 2026

  “Drugs/Equipment Unavailable”Registry text, quoted unchanged. Source

• Suspended

  A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  NCT05691478· National Cancer Institute (NCI)· Updated 27 Oct 2026

  “Other - Extend the observation period for current patients”Registry text, quoted unchanged. Source

• Suspended

  Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

  NCT05756660· Children's Hospital Medical Center, Cincinnati· Updated 22 Oct 2026

  “This study will be closing at CCHMC and may be transferred to a principal investigator at another insitutiton.”Registry text, quoted unchanged. Source

• Terminated

  Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

  NCT03904862· Pediatric Brain Tumor Consortium· Updated 19 Oct 2026

  “The decision to permanently close PBTC-053 was made following communication from the NCI that the PBTC grant will not be extended beyond March 31, 2026.”Registry text, quoted unchanged. Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Updated 16 Oct 2026

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”Registry text, quoted unchanged. Source

• Suspended

  Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

  NCT07052383· Tcelltech Inc.· Updated 14 Oct 2026

  “Data update in progress.”Registry text, quoted unchanged. Source

• Terminated

  Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors

  NCT04485416· University of California, Davis· Updated 9 Oct 2026

  “PI discretion; suspended while CAPA is reviewed”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

  NCT05621291· National Cancer Institute (NCI)· Source

• The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

  NCT05436418· National Cancer Institute (NCI)· Source

• Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

  NCT07524530· National Cancer Institute (NCI)· Source

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

  NCT07437963· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· National Cancer Institute (NCI)· Source

• A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Hoffmann-La Roche· Source

• Data Collection, Clinical Care and Interventions in CCR, NCI

  NCT00923065· National Cancer Institute (NCI)· Source

• Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Institut Curie· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 123
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 30
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 86
• Immunohistochemistry 197
• Liquid Biopsy 24
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 516
• Machine Learning 66
• Deep Learning 25
• Cohort Studies 327
• Genome-Wide Association Study 22

• Unveiling Cerebrospinal Fluid Protein Biomarkers in Pediatric Acute Lymphoblastic Leukemia Using a Proximity Extension Assay.

  J Proteome Res, Nov 2026

• Biomineralized SERS Nanotags Encode Biomolecular Identity into Machine Learning-Resolvable Fingerprints.

  ACS Appl Mater Interfaces, Sept 2026

• Radiomics and machine learning for differentiating pediatric intramedullary spinal tumors: a pilot study.

  Eur Radiol Exp, Sept 2026

• Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis.

  Curr Oncol Rep, Sept 2026

• Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma.

  Cancer Med, Sept 2026

• Evaluating the impact of segmentation strategies on radiomic feature stability for paediatric brain tumour diagnosis using diffusion weighted imaging.

  PLoS One, Aug 2026

• Harmonizing Multi-Institutional Clinical Documentation Using Natural Language Processing in Neurofibromatosis Type 1.

  Neurol Clin Pract, Aug 2026

• A Machine Learning Pipeline to Analyze Global Sentiment and Factors Influencing Retinoblastoma Treatment Hesitancy: Observational Infodemiology Study.

  J Med Internet Res, Aug 2026

• Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.

  Sci Rep, Aug 2026

• A Non-enhanced CT Dataset for Differential Diagnosis of Pediatric Extracranial Germ Cell Tumors.

  Sci Data, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.